Figitumumab - Pfizer
Alternative Names: Anti-IGF-1R monoclonal antibody - Pfizer; CP-751,871Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action IGF type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Gastrointestinal cancer; Gynaecological cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Rheumatoid arthritis; Sarcoma; Small cell lung cancer; Solid tumours
Most Recent Events
- 02 Mar 2011 Discontinued - Phase-I for Multiple myeloma in USA (IV)
- 28 Feb 2011 Discontinued - Phase-I for Solid tumours in Canada (IV)
- 28 Feb 2011 Discontinued - Phase-I for Solid tumours in Finland (IV)